LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Search

TG Therapeutics Inc

Fechado

SetorSaúde

29.38 2.26

Visão Geral

Variação de preço das ações

24h

Atual

Mín

28.39

Máximo

29.48

Indicadores-chave

By Trading Economics

Rendimento

23M

28M

Vendas

20M

141M

P/E

Médio do Setor

74.946

35.473

Margem de lucro

19.97

Funcionários

370

EBITDA

25M

38M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+13.56% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-104M

4.5B

Abertura anterior

27.12

Fecho anterior

29.38

Sentimento de Notícias

By Acuity

100%

0%

361 / 372 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

TG Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de ago. de 2025, 23:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22 de ago. de 2025, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22 de ago. de 2025, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22 de ago. de 2025, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22 de ago. de 2025, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22 de ago. de 2025, 22:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22 de ago. de 2025, 21:23 UTC

Conversa de Mercado

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22 de ago. de 2025, 21:18 UTC

Conversa de Mercado

US Economic Growth Seen Slowing This Year -- Market Talk

22 de ago. de 2025, 21:18 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Takes 10% Stake in Intel -- Barrons.com

22 de ago. de 2025, 21:03 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 de ago. de 2025, 21:03 UTC

Conversa de Mercado

Mexican Stocks Close At Record High -- Market Talk

22 de ago. de 2025, 20:58 UTC

Conversa de Mercado

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22 de ago. de 2025, 20:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22 de ago. de 2025, 20:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22 de ago. de 2025, 20:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22 de ago. de 2025, 20:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22 de ago. de 2025, 20:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22 de ago. de 2025, 20:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22 de ago. de 2025, 20:56 UTC

Ganhos

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 de ago. de 2025, 20:55 UTC

Ganhos

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 de ago. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

22 de ago. de 2025, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

22 de ago. de 2025, 20:41 UTC

Aquisições, Fusões, Aquisições de Empresas

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22 de ago. de 2025, 20:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22 de ago. de 2025, 20:16 UTC

Aquisições, Fusões, Aquisições de Empresas

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22 de ago. de 2025, 19:19 UTC

Conversa de Mercado

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22 de ago. de 2025, 19:10 UTC

Conversa de Mercado

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22 de ago. de 2025, 19:06 UTC

Conversa de Mercado

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22 de ago. de 2025, 19:03 UTC

Conversa de Mercado

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22 de ago. de 2025, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Comparação entre Pares

Variação de preço

TG Therapeutics Inc Previsão

Preço-alvo

By TipRanks

13.56% parte superior

Previsão para 12 meses

Média 32.67 USD  13.56%

Máximo 50 USD

Mínimo 11 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para TG Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

3 ratings

1

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 34.86Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

361 / 372 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.